Cited by

• Preparation of biodegradable microspheres and matrix devices containing naltrexone.

  Dinarvand R, Moghadam SH, Mohammadyari-Fard L, Atyabi F. Dinarvand R, et al. AAPS PharmSciTech. 2003;4(3):E34. doi: 10.1208/pt040334. AAPS PharmSciTech. 2003. PMID: 14621966 Free PMC article.
• The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects.

  Lo MW, Lee FH, Schary WL, Whitney CC Jr. Lo MW, et al. Eur J Clin Pharmacol. 1987;33(3):297-301. doi: 10.1007/BF00637566. Eur J Clin Pharmacol. 1987. PMID: 3691617
• Buprenorphine: Far Beyond the "Ceiling".

  Infantino R, Mattia C, Locarini P, Pastore AL, Maione S, Luongo L. Infantino R, et al. Biomolecules. 2021 May 31;11(6):816. doi: 10.3390/biom11060816. Biomolecules. 2021. PMID: 34072706 Free PMC article. Review.
• Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.

  Huestis MA, Cone EJ, Pirnay SO, Umbricht A, Preston KL. Huestis MA, et al. Drug Alcohol Depend. 2013 Aug 1;131(3):258-62. doi: 10.1016/j.drugalcdep.2012.11.014. Epub 2012 Dec 14. Drug Alcohol Depend. 2013. PMID: 23246635 Free PMC article. Clinical Trial.
• Which potent opioid? Important criteria for selection.

  Bovill JG. Bovill JG. Drugs. 1987 May;33(5):520-30. doi: 10.2165/00003495-198733050-00006. Drugs. 1987. PMID: 2954811